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r F. Crawford (Charleston, SC): Drs Feindel and Mitchell, I
ave no conflicts to disclose. I enjoyed this presentation very
uch. PPM after aortic valve replacement has been discussed at
ength in recent years, although there is far from universal agree-
ent about the potential implications of such mismatch. Far less
nformation is available about PPM in the mitral position. Several
mportant differences between the aortic and mitral position exists
s indicated by the authors, including limited options for implant-
ng large valves in the mitral positions and inferior types of
rostheses available for MVR. In addition, PPM in the aortic
osition may adversely affect left ventricular function, whereas in
he mitral position it is usually right ventricular function that is
ffected.
In this excellent article that describes a large series of patients
ho underwent MVR and were followed prospectively by the
uthors, IEOA did not predict persistent PHTN, which has gener-
lly been considered an important factor predicting outcomes after
VR. I have several questions for the authors.
If PHTN was not associated with PPM, what do you postulate
s the reason for the poorer outcomes in your patients?
Second, what percentage of your patients had chordal-sparing
VR, and was the lack of such a chordal-sparing procedure an
ndependent risk factor for poorer outcomes?
Finally, in the article you state, “We recommend avoidance of
bioprosthesis in patients with possible MVPPM criteria.” Does
his mean that you would therefore recommend using a mechanical
rosthesis in such a patient even if the patient were elderly and that
ou therefore believe the potential risk of MVPPM in such a
atient outweighs the known risk of long-term anticoagulation
ith Coumadin?
Dr Lam: With regard to the lack of correlation between the
EOA and PHTN in this study, I must say that although our
ollow-up is prospective in nature and we gather as many echo-
ardiograms as we can, when we look at the data with regard to the
vailability of the SPAP, these are not always reported consistently
n all of our echocardiogram reports. Therefore, we are likely
nderpowered to detect the link between IEOA and PHTN. This
ould mean that some of our patients, who had lower IEOAs or
OAs, likely did not have the PHTN variable available for anal-
sis.
With regard to the possible explanations as to why patients with
HTN do not fare as well; it is difficult to explain. I think that, at
his point, the correlation between IEOA and other echocardio-
raphic markers, such as gradients or PHTN, remains unclear in
he literature. Some studies have found correlations, and others
ave not. At this point I can’t tell you for sure what would be an
dequate marker to be associated with a worse IOA, whether it can
e the gradients, PHTN, or aortic valve compliance. The latter has
een suggested as a newer potential clinical marker that could be
onitored. Once these markers are established, we still have toorrelate them with clinical outcomes. s
472 The Journal of Thoracic and Cardiovascular Surgery ● JunWith regard to your question on chordal preservation, this study
s somewhat historical in nature and spans 20 years. Certainly our
ractice currently is to do chordal preservation, but that has
hanged over the years and that data are not entirely available in all
atients, so therefore I am not able to answer that question.
With regard to the use of biological valves, I think that we
urrently abide by all the guidelines with regard to the use of an
ppropriate valve for the patient size and risk factors. There are
arious sizes in terms of valves, and each valve brand has an EOA
hat is variable. I think the take-home message is that we should try
nd insert the largest EOA valve possible irrespective of brand,
nd that varies from one brand name to the other. Certainly we
ould not subject a patient to the undo risk of anticoagulation if
e found an adequate sized biological valve for the annulus.
Dr R. Martinez-Sanz (Tenerife, Spain): In mitral insufficiency
hen a mitral ring is performed, the aim is to reduce the posterior
nnulus, undersizing this as much as 26 mm, 28 mm, or less. For
his reason, when mitral repair is not possible, we perform MVR
sing a 27- or 25-mm valve prosthesis with less hospital mortality
nd postoperative complications than when using a bigger pros-
hesis. Now we are studying the follow-up of this class of patients.
The question is, in your study, do you know how many patients
ith undersized prostheses there were?
Dr Lam: To answer your question, this table illustrates the in
ivo EOA used in this study according to valve and valve size; as
ou can see, some of these valves, highlighted in green, have
maller EOAs to begin with. Once this is indexed, there is a
ariability with regard to each valve, and this is, of course, depen-
ent on your patient population, but this is our patient population
nd what their index was. So the green areas are the areas of
rouble, and we have noticed them in this type of valve, the
ioprosthesis, and we have noticed them in the larger patients.
Now, the larger patients, one of the things that we do know is
hat the literature has few EOA publications and the sample sizes
re relatively small. So we are going by a small number, but it
eems to suggest that for the larger sized patients, the valves that
re out there right now may not have an appropriately sized EOA,
nd that is what we found in our study.
Dr Martinez-Sanz: This is for the whole group, not for the
itral regurgitation group only?
Dr Lam: I unfortunately do not have data for the mitral
egurgitation group specifically.
Dr E. Jamieson (Vancouver, Canada): Congratulations for
ringing this topic forward. Some of my questions have been
nswered, but a couple are, how confident are you that a break-off
f 1.25 does not require further investigation? The second has been
artially answered by your last slide, but the other question is
elated to your large experience with the On-X valve. As we all
now, the size of the orifice is 25 mm regardless of whether you
re using a 25 or 31; how did you handle that and did you find any
iscrepancies in performance?
Dr Lam: With regard to the On-X valve, you are right, the
alve in this scenario seemed to perform adequately except for the
arger sized valves, and as I just mentioned, I think that this needs
o be revisited in terms of an appropriately sized valve for a larger
atient per se. We have done the analyses on various segments of
EOAs, going from 1.5 to 1.0 cm2/m2. Clinical correlations are
trongest when you hit 1.0 cm2/m2. However, I think that in terms
e 2007
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CDf clinical outcomes, the significant cutoff in this study was ap-
roximately 1.25 cm2/m2, and that is why we used the 1.25
m2/m2. The range that is given in the literature varies from 1.2 to
.5 cm2/m2, and that is based on pulse duplicator data on small
ample sizes to establish echocardiographic correlations. To put
hat into a clinical context, we had to do the analysis over a wide
ange of IEOAs.
Dr Pasquale Totaro (Palermo, Italy): First of all, I congratu-
ate you for addressing such an important issue that has been
lmost ignored for a long time. I have done a similar study, and I
m going to present my results during an European meeting in due
ourse. The data I am going to present are different from the data
ou presented today. By using only stented Carpentier-Edwards
ioprosthesis and evaluating the PPM based on the postoperative
n vivo IEOA, we found an incidence of PPM less than 10%, and
his included patients with a size 25 bioprosthesis.
Did you evaluate PPM on the basis of in vivo postoperative
chocardiogram data on your patients? Did you find any difference
etween mechanical and biological prostheses?
Dr Lam: We have not performed the analysis yet, but the data
re available. We didn’t look at that specifically. We specifically
ooked at our MVPPMs and what their gradients were, but that is
n excellent point.
I think that when you look at the data with regard to EOA, there
re 2 ways to go about it: (1) Ask your echocardiographer to
ctually do the measurements by the continuity equation, not the
ressure half time, which is not as reliable. (2) Review the litera-
ure and garner all the EOAs possible that were published based on
n vivo echo measurements and not laboratory or pulse duplicator
ata, which are sometimes what you get when you get the little d
The Journal of Thoracicamphlet from the companies giving you different EOAs. If the
atter is what you have done, then we should probably have to
ompare our mutual results.
Dr Totaro: So these are not data that you calculated in vivo
ostoperatively?
Dr Lam: No. We used averaged EOAs from the studies in the
iterature.
Dr Totaro: I think that this could make a real impact and
xplain the difference between our results .
Dr Guo-Wei He (Hong Kong, China): Dr Lam, this is an
mportant study, particularly, as Dr Crawford says, the mitral valve
nd the patient mismatch was not the same as the aortic valve and
he patient mismatch. A few years ago we published a study in the
ournal on aortic valve mismatch with patient body surface area,
nd what we found was with a body surface area more than 1.6,
hen you use a small aortic prosthesis, including a 19- and a
0-mm prosthesis, there was less long-term survival.
Your study is interesting and scientifically accurate, but in
linical practice to use your study to look at EOA is complicated
or a practicing surgeon. Can you simplify your study to look at,
hen a patient’s body surface area is more than 1.5, 1.6, 1.7, and
.8, a small mitral size such as 25 plus 27 compared with the larger
roup? To simplify your results, can you do it that way, or maybe
ou have done that?
Dr Lam: That is definitely possible to do. We have the data set,
nd it wouldn’t be out of the scope of the completion of this
roject. I think that in terms of clinical information it would be
uch easier to interpret, as you said, and that is something we willefinitely look into.
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